| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of common stock under the 2025 employee stock purchase plan | 612 | 612 |
| Payment of success fee derivative | 500 | 500 |
| Net cash provided by financing activities | 271,747 | 127,990 |
| Net increase in cash, cash equivalents, and restricted cash | 119,962 | 67,730 |
| Cash and cash equivalents at beginning of period | 197,900 | - |
| Cash and cash equivalents at end of period | 317,862 | - |
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)